Heparin-induced thrombocytopenia associated with fondaparinux

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 1, 2010, Pages 63-65

  Chong, Beng H ^a,b   Chong, James J H ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; DRUG ANTIBODY; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FONDAPARINUX INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LUNG EMBOLISM; NOTE; PATHOPHYSIOLOGY; POSTOPERATIVE THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET COUNT; POLYSACCHARIDES; THROMBOCYTOPENIA;

EID: 76149086521     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356:2653-2655.
2. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008;99:779-781.
3. Warkentin TE, Lim W. Can heparin-induced thrombocytopenina be associated with fondaparinux use?. Reply to a rebuttal. J Thromb Haemost. 2008;6: 1243-1246.
4. Alsaleh KA, Al-Nasser SMA, Bates SM, Patel A, Warkentin TE, Arnold DM. Delayed-onset HIT caused by low-molecular weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol. 2008;83:876-878.
5. Chong BH, Du X-P, Berndt MC, Horn S, Chesterman CN. Characterisation of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood. 1991;77:2190-2199.
6. Chong BH. Heparin-induced thrombocytopenia (State of Art Paper). J Thromb Haemostat. 2003;1:1471-1478.
7. Chong BH, Castaldi PA, Berndt MC. Heparin-induced thrombocytopenia: effects of rabbit IgG and its Fab and Fc fragments on antibody-heparin-platelet interaction. Thrombosis Research. 1989;55:291-295.
8. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigen recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26:2386-2393.
9. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaprin. Blood. 2005;106:3791-3796.
10. Vun CH, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res. 1996; 81:525-532.
11. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicentre study with unfractionated heparin. Blood. 2005;105:139-144.
12. Ratuapli SK, Bobba B, Zafar H. Heparin induced thrombocytopenia in a patient treated with fondaparinux. Clin Adv Hematol Oncol. 2010;8:61-62.
13. Chong BH, Gallus AS, Cade J, Manoharan A, Magnani H, Chesterman CN. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost. 2001;86:1170-1175.